Answers are grounded in this paper and cite their sources.
This editorial discusses the rationale and considerations for deprescribing beta-blockers in post-MI patients treated with contemporary secondary prevention therapies.
Editorials ◼ heart rate ◼ myocardial infarction ◼ prescriptions I n patients hospitalized with myocardial infarction (MI), advances in reperfusion therapies, systems of care, and secondary prevention have contributed to a decline in mortality over the past 60 years. 1 Randomized trials conducted >40 years ago demonstrated that both early intravenous and subacute oral β-blocker administration reduced mortality in patients presenting with an acute MI.Decades of subsequent research into adjunctive pharmacotherapies have contributed to frequent polypharmacy in this patient population. 2 This increased pill burden has the potential to contribute to decreased adherence, as well as increased side effects (eg, hypotension, bradycardia, depression, new-onset diabetes with β-blockers) and healthcare costs.3,4 Before recent evidence became available, the efficacy of older therapies, such as β-blockers, remained uncertain when prescribed along with contemporary vascular protective treatments (eg, angiotensin-converting enzyme inhibitors, statins, antiplatelet agents).
No takes yet. Share an insight, caveat, or question.
Diepen et al. (2026) conducted an editorial in Myocardial infarction. Beta-blocker deprescription was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: